Tris Pharma, Inc. and Athena Bioscience LLC have entered an agreement granting Athena exclusive rights to commercialize a long-acting antihypertensive product developed using Tris’ proprietary technology.    The product aims to address patient adherence to chronic disease medications. In the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death. The licensed ...